First, in cutaneous melanoma samples from TCGA and GEO, the differentiation of samples with or without resistance to targeted therapy and immune therapy was not considered, nor were BRAF/NRAS mutations in patient tumors. This evidence concerns the gene NRAS and cutaneous melanoma.